Zydus Cadila gets USFDA nod for high blood sugar control tablets

Indian pharmaceutical company, Zydus Cadila, announced in a BSE filing made during the weekend that it has received an approval to market Empagliflozin & Metformin Hydrochloride tablets, 5 mg/500 mg, 5 mg/1,000 mg, 12.5 mg/500 mg and 12.5 mg/1,000 mg (US RLD: Synjardy tablets) from US Food & Drug Administration (USFDA). The products will be manufactured at the group’s formulation facility at SEZ in Ahmedabad.

Adding to this, the company said that the above-mentioned tablets are a combination of two drugs, that is, Empagliflozin and Metformin, which helps people with Type-2 diabetes in controlling high blood sugar. It proves beneficial when taken with a proper diet and a good exercise plan.

Zydus Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures as well as markets a broad range of healthcare products. The group so far, has 289 approvals and 286 ANDAs, since the commencement of the filing process in FY 2003-2004.

At 10.33 am on Monday, the stock of Cadila Heathcare Ltd is trading at Rs 332.10, up by 2.52 per cent against its previous close of Rs 323.95. Its 52-week high is Rs 378.00 while, its 52-week low is Rs 206.45 on BSE.